Literature DB >> 28705706

Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions.

Mio Tanaka1, Kenichi Kohashi2, Kei Kushitani3, Misa Yoshida4, Sho Kurihara5, Masumi Kawashima5, Yuka Ueda5, Ryota Souzaki6, Yoshiaki Kinoshita6, Yoshinao Oda2, Yukio Takeshima3, Eiso Hiyama5, Tomoaki Taguchi6, Yukichi Tanaka4.   

Abstract

We report 2 infantile cases of pulmonary tumor carrying a chimeric A2M-ALK gene. A2M-ALK is a newly identified anaplastic lymphoma kinase (ALK)-related chimeric gene from a tumor diagnosed as fetal lung interstitial tumor (FLIT). FLIT is a recently recognized infantile pulmonary lesion defined as a mass-like lesion that morphologically resembles the fetal lung. Grossly, FLIT characteristically appears as a well-circumscribed spongy mass, whereas the tumors in these patients were solid and firm. Histologically, the tumors showed intrapulmonary lesions composed of densely proliferating polygonal or spindle-shaped mesenchymal cells with diffuse and dense infiltrations of inflammatory cells forming microcystic or micropapillary structures lined by thyroid transcription factor 1-positive pneumocytes, favoring inflammatory myofibroblastic tumor rather than FLIT. The proliferating cells were immunoreactive for ALK, and A2M-ALK was identified in both tumors with reverse-transcription polymerase chain reaction. The dense infiltration of inflammatory cells, immunoreactivity for ALK, and identification of an ALK-related chimeric gene suggested a diagnosis of inflammatory myofibroblastic tumor. Histologically, most reported FLITs show sparse inflammatory infiltrates and a relatively low density of interstitial cells in the septa, although prominent infiltration of inflammatory cells and high cellularity of interstitial cells are seen in some FLITs. The present cases suggest that ALK rearrangements, including the chimeric A2M-ALK gene, may be present in these infantile pulmonary lesions, especially those with inflammatory cell infiltration. We propose that these infantile pulmonary lesions containing a chimeric A2M-ALK gene be categorized as a specific type of inflammatory myofibroblastic tumor that develops exclusively in neonates and infants.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chimeric A2M-ALK gene; Fetal lung interstitial tumor; Immunohistochemistry; Inflammatory myofibroblastic tumor; Reverse-transcription polymerase chain reaction

Mesh:

Substances:

Year:  2017        PMID: 28705706     DOI: 10.1016/j.humpath.2017.06.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.

Authors:  Fernando Vargas-Madueno; Edwin Gould; Raul Valor; Nhu Ngo; Linsheng Zhang; Miguel A Villalona-Calero
Journal:  Oncologist       Date:  2018-05-08

2.  Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay.

Authors:  Marie-Delphine Lanic; François Le Loarer; Vinciane Rainville; Vincent Sater; Mathieu Viennot; Ludivine Beaussire; Pierre-Julien Viailly; Emilie Angot; Isabelle Hostein; Fabrice Jardin; Philippe Ruminy; Marick Laé
Journal:  Mod Pathol       Date:  2022-01-24       Impact factor: 7.842

3.  Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile.

Authors:  Steven D Billings; Jennifer S Ko; Josephine K Dermawan; Elizabeth M Azzato; John R Goldblum; Brian P Rubin
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

4.  Spontaneous pneumothorax caused by an inflammatory myofibroblastic tumor-like lesion in a 14-year-old girl: a case report.

Authors:  Hisayuki Miyagi; Daisuke Ishii; Masatoshi Hirasawa; Shunsuke Yasuda; Naohisa Toriumi; Takeo Sarashina; Mishie Tanino; Mio Tanaka; Yukichi Tanaka; Kazutoshi Miyamoto
Journal:  Surg Case Rep       Date:  2020-05-24

Review 5.  Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.

Authors:  Hao Huang
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

6.  Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour.

Authors:  Abhenil Mittal; Aarushi Gupta; Sameer Rastogi; Adarsh Barwad; Swati Sharma
Journal:  Ecancermedicalscience       Date:  2021-04-01

7.  Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.

Authors:  Jeongwan Kang; Jin Woo Park; Jae-Kyung Won; Jeong Mo Bae; Jaemoon Koh; Jeemin Yim; Hongseok Yun; Seung-Ki Kim; Jung Yoon Choi; Hyoung Jin Kang; Woo Sun Kim; Joo Heon Shin; Sung-Hye Park
Journal:  Diagn Pathol       Date:  2020-09-21       Impact factor: 2.644

8.  Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.

Authors:  Tien-Chi Hou; Pao-Shu Wu; Wen-Yu Huang; Yi-Ting Yang; Kien Thiam Tan; Shih-Hua Liu; Yu-Jen Chen; Shu-Jen Chen; Ying-Wen Su
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.